Related by context. All words. (Click for frequent words.) 71 chronic HBV infection 70 hepatitis C virus 69 chronic HCV infection 68 HCV 68 chronic HCV 68 CMV disease 68 S. aureus infections 68 HCV infections 67 LTBI 67 HCV infected 66 indolent NHL 66 CMV infection 65 H pylori 65 superinfection 65 MGUS 65 HBV infection 65 invasive candidiasis 65 hepatitis C HCV 65 candidemia 65 hepatitis C infection 65 hepatocellular carcinoma HCC 65 chronic HBV 65 hepatitis C genotype 65 EBV infection 65 invasive fungal infection 64 invasive aspergillosis 64 chlamydial infection 64 hepatocellular carcinoma 64 nucleoside analogues 64 superficial bladder cancer 64 genital herpes infections 64 MDR tuberculosis 64 Epstein Barr virus EBV 64 P. vivax malaria 63 CCR5 tropic HIV 63 NNRTI resistance 63 AEG# 63 nucleotide analog 63 acute leukemias 63 multidrug resistance 63 leukemia ALL 63 NRTI resistance 63 latent TB infection 63 antitumor effect 63 Chlamydia trachomatis 63 HPV infections 63 CDAD 63 nonmelanoma skin cancers 63 herpesviruses 63 lupus nephritis 63 HNSCC 63 HBeAg negative 63 latent tuberculosis infection 63 PCNSL 62 metastatic RCC 62 Staphylococcus aureus infections 62 hepatitis B virus HBV 62 neuroendocrine cancers 62 CCR5 tropic 62 carcinoid tumors 62 advanced NSCLC 62 Candida species 62 viral subtypes 62 WNV infection 62 mRCC 62 leukaemias 62 peginterferon 62 HBV 62 TREANDA 62 follicular lymphoma 62 CYT# potent vascular disrupting 62 pneumococcal serotypes 62 pneumococcal infection 62 familial ALS 62 Hepatitis C virus 62 M#V mutation 62 Velcade bortezomib 62 HCV genotype 1 62 Chronic lymphocytic leukemia 62 pharmacokinetic interactions 62 acute myelogenous leukemia AML 62 nosocomial pneumonia 62 cervical lesions 62 basal cell carcinoma BCC 62 OHR/AVR# 62 fluoroquinolone resistance 62 cervical intraepithelial neoplasia 61 VZV 61 gastric adenocarcinoma 61 acute promyelocytic leukemia 61 S. aureus infection 61 Helicobacter pylori H. pylori 61 relapsed ovarian cancer 61 Trichomonas vaginalis 61 EGFR inhibitors 61 invasive cervical cancer 61 sustained virological response 61 HPV# 61 antiviral therapy 61 relapsed MM 61 osteosarcomas 61 Chlamydia pneumoniae 61 heavily pretreated 61 hepatitis C virus HCV 61 C. trachomatis 61 relapsed leukemia 61 myeloproliferative disorders 61 entecavir 61 prostate cancer CaP 61 refractory gout 61 recurrent genital herpes 61 colorectal cancer CRC 61 epithelial tumors 61 tigecycline 61 bendamustine 61 lymphomas 61 leukemia AML 61 NNRTIs 61 herpes zoster shingles 61 NOMID 61 HER2 overexpression 61 Hepatitis C virus HCV 61 malignant pleural mesothelioma 61 HCV genotype 61 bacteraemia 61 recurrent VTE 61 HSV1 61 nitazoxanide 61 hepatitis B infection 61 Pseudomonas aeruginosa infections 61 elotuzumab 61 HPV infection 61 cholangiocarcinoma 61 dasatinib 61 chlamydial 61 systemic lupus erythematosus SLE 61 CD8 responses 61 CLL 61 noninfectious uveitis 61 Candida infection 61 chronic hepatitis 61 Clostridium difficile infections 61 micafungin 61 neuroendocrine tumors 61 daptomycin 61 metastatic neuroendocrine tumors 61 posaconazole 61 basal cell nevus syndrome 61 virological failure 60 Virulizin ® 60 leukemia CLL 60 varicella infection 60 Hepatocellular Carcinoma HCC 60 imatinib resistance 60 hematological malignancy 60 elevated triglyceride levels 60 metastatic malignant melanoma 60 pneumococcal pneumonia 60 virological response 60 medulloblastomas 60 T#I mutation 60 MRSA strains 60 OncoVEX GM CSF 60 liver transplantations 60 virologic failure 60 BRAF mutation 60 coinfected 60 virus HCV infection 60 ADPKD 60 EGFR mutation 60 Zolinza 60 HPV types 60 sustained virologic response 60 severe sepsis 60 sCJD 60 nonvaccine 60 oral antiviral 60 PROSTVAC VF 60 pomalidomide 60 staphylococcal infections 60 thalidomide Thalomid 60 SSc 60 chronic hepatitis C 60 liver metastases 60 chronic hepatitis C. 60 microbiological eradication 60 grade cervical intraepithelial 60 vWD 60 HCV SPRINT 60 vivax malaria 60 Gleevec resistant 60 acute GvHD 60 hepatocellular cancer 60 EGFR mutations 60 squamous cell lung cancer 60 pancreatic NET 60 skeletal metastases 60 DFMO 60 nonmelanoma skin cancer 60 Altastaph 60 Genital herpes 60 serotype #A 60 JAK3 60 neutralizing antibody 60 HER2 positive breast cancer 60 chronic hepatitis B. 60 latent TB 60 oral prodrug 60 pancreatic adenocarcinoma 60 bone metastasis 60 multidrug resistant 60 nonalcoholic steatohepatitis NASH 60 CMV infections 60 immunosuppressive therapies 60 GBM tumors 60 nucleoside analogs 60 alkylating agent 60 cirrhosis liver failure 60 chemotherapy induced neutropenia 60 Renal Cell Carcinoma RCC 60 Tindamax R 60 SCCHN 60 doripenem 60 immunocompetent 60 TGFBR1 * 6A 60 Apaziquone 60 Kaposi sarcoma 60 PegIFN RBV 60 HuLuc# 60 TTR amyloidosis 60 genital ulcers 60 HPV-#/# 60 immunodeficiency 60 dasatinib Sprycel 60 simplex virus 60 OMAPRO 60 H. pylori infection 59 HIV HCV coinfected 59 pediatric acute lymphoblastic 59 retinal vein occlusion 59 allogeneic HSCT 59 ribavirin therapy 59 Bcr Abl mutations 59 elacytarabine 59 antithrombotic 59 non Hodgkin lymphomas 59 complete cytogenetic response 59 cell lymphomas 59 GISTs 59 K ras mutations 59 JAK inhibitor 59 Doxil ® 59 GIST tumors 59 replicon 59 neutralizing antibodies 59 gastric cancer 59 BCR ABL mutations 59 Amigal 59 NSCLC 59 M. leprae 59 reinfection 59 HPV subtypes 59 DLBCL 59 predictive biomarkers 59 Chlamydia infection 59 CCR5 antagonist 59 invasive fungal infections 59 P. vivax 59 coinfection 59 vivax 59 AA amyloidosis 59 prostate adenocarcinoma 59 chronic lymphocytic leukemia CLL 59 FGFR2 59 anti TNF 59 Xanafide 59 hepatoma 59 HIV infection 59 NS4A 59 metastatic gastric 59 colorectal liver metastases 59 Bezielle 59 carcinoid 59 renal toxicity 59 cIAI 59 talabostat 59 chronic periodontitis 59 COPD exacerbations 59 Clostridium difficile associated 59 PKC# 59 cytomegalovirus infection 59 serogroups 59 HCV genotypes 59 G#DT 59 sJIA 59 prostate cancer CRPC 59 antiviral therapies 59 ACZ# 59 disease CDAD 59 diabetic nephropathy 59 Plasmodium falciparum malaria 59 raltegravir 59 parainfluenza virus 59 imatinib therapy 59 erlotinib Tarceva ® 59 MEK inhibitors 59 elvucitabine 59 oropharyngeal cancer 59 lapatinib Tykerb 59 chronic GVHD 59 DermaVir Patch 59 pneumococcal infections 59 relapsed multiple myeloma 59 Leukemias 59 Chronic hepatitis B 59 treatment naïve genotype 59 JVRS 59 tuberculin skin testing 59 genital ulcer disease 59 VFEND 59 cSSSIs 59 HoFH 59 basal cell carcinomas 59 HCV replicon 59 idiopathic pulmonary fibrosis IPF 59 systemic lupus erythematosus 59 Natalizumab 59 nephrotoxicity 59 ATL/TV# 59 FluCide 59 intravenous bisphosphonates 59 adalimumab 59 differentiated thyroid 59 cisplatin chemotherapy 59 Amplimexon 59 chlorambucil 59 Hib disease 59 ALT flares 59 Atypical Hemolytic Uremic Syndrome 59 S. aureus bacteremia 59 bacterial pneumonias 59 Hepatitis B virus 59 nucleotide analogs 59 HER2 positive cancers 59 efalizumab 59 falciparum malaria 59 malignant lymphoma 59 mitochondrial toxicity 59 galiximab 59 antithrombotics 59 latent tuberculosis 59 nosocomial infection 59 immunosuppressive regimens 59 lumiliximab 59 Cholangiocarcinoma 59 neuroblastoma tumors 59 riociguat 59 CMV retinitis 59 T2DM 59 myeloproliferative diseases 59 Toxicities 59 treatment naive genotype 59 TACI mutations 59 H. pylori eradication 59 RSV infections 59 JAK inhibitors 59 Traficet EN 59 gefitinib Iressa 59 Hepatitis C Virus HCV 58 HBV vaccine 58 atypical hemolytic uremic syndrome 58 falciparum 58 virotherapy 58 iclaprim 58 respiratory viral infections 58 elevated CRP 58 dengue viruses 58 Epstein Barr Virus EBV 58 chemotherapeutic regimens 58 null responder 58 pleural mesothelioma 58 PCa 58 imipenem 58 BRAF V# mutation 58 invasive meningococcal disease 58 rifamycins 58 AAT deficiency 58 chronic HCV genotype 58 relapsing remitting MS RRMS 58 metastatic disease 58 Viramidine 58 external genital lesions 58 pheochromocytoma 58 HQK 58 coinfected patients 58 refractory CLL 58 rindopepimut 58 VUR 58 chronic myeloid leukemia CML 58 medulloblastoma 58 tipranavir 58 ano genital warts 58 Symadex 58 pharmacologic intervention 58 Hodgkin lymphoma HL 58 varicella zoster virus VZV 58 myelofibrosis polycythemia vera 58 disease progression 58 papillary renal cell carcinoma 58 FSGS 58 azacitidine 58 KRAS status 58 inhibit replication 58 LHRH antagonists 58 octreotide LAR 58 lesinurad 58 renal cell carcinomas 58 human herpesvirus 58 MGd 58 IMA# 58 HeFH 58 protease inhibitors PIs 58 sexually transmitted HPV 58 Plasmodium vivax 58 MyVax R 58 CA MRSA infections 58 recurrent glioblastoma multiforme 58 metastatic lung cancer 58 locoregional recurrence 58 velafermin 58 Candida infections 58 systemic scleroderma 58 non nucleoside HCV 58 FLT3 58 viral hemorrhagic fevers 58 sorafenib Nexavar 58 G CSF 58 BEXXAR 58 acute rheumatic fever 58 hypophosphatasia 58 PTLD 58 S. pyogenes 58 malignant neoplasms 58 MDR TB 58 ocrelizumab 58 rotavirus diarrhea 58 topotecan 58 enzastaurin 58 heterozygous FH 58 advanced adenoma 58 Helicobacter 58 sargramostim 58 multidrug resistant strains 58 malignancies 58 Fludara ® 58 anticancer therapies 58 chemopreventive agent 58 chemoresistance 58 chronic hepatitis B 58 multiple myeloma MM 58 panobinostat 58 medullary thyroid cancer 58 HBeAg positive 58 trabectedin 58 Aspergillus infections 58 grade gliomas 58 multidrug resistant TB MDR 58 variceal bleeding 58 BRAF gene 58 SHPT 58 trastuzumab Herceptin ® 58 Cloretazine 58 pegylated interferons 58 serologic 58 fluconazole resistant 58 Squamous 58 Janus kinase 58 HAART regimens 58 P. aeruginosa infections 58 ADHF 58 chronic ITP 58 invasive pneumococcal disease 58 mycosis fungoides 58 relapsed AML 58 sorafenib Nexavar ® 58 dapsone 58 chronically infected 58 Plasmodium falciparum 58 S. aureus colonization 58 interferon ribavirin 58 clade B 58 lung adenocarcinoma 58 PRTX 58 PANVAC VF 58 efavirenz Sustiva 58 castration resistant prostate cancer 58 NATRECOR ® 58 Azedra 58 IGF 1R inhibitor 58 venous blood clots 58 anal cancers 58 Genasense ® 58 NNRTI 58 forodesine 58 hematological cancers 58 familial pancreatic cancer 58 acute GVHD 58 vismodegib 58 S.aureus 58 tivozanib 58 TNF antagonist 58 PTEN mutations 58 Arcalyst 58 breast carcinomas 58 serogroup B 58 S. aureus isolates 58 CaP 58 relapsed SCLC 58 Acute Myeloid Leukaemia AML 58 lenalidomide Revlimid R 58 MYH9 gene 58 nonsmall cell lung cancer 58 human metapneumovirus 58 ALK inhibitors 58 C. difficile infection 58 liver fibrosis 58 sporadic ALS 58 Arranon 58 ganciclovir 58 UPLYSO 58 brain metastases 58 CHOP chemotherapy 58 delayed CINV 58 combination antiretroviral therapy 58 S aureus 58 KRAS mutations occur 58 lymphoid tumors 58 interferon 58 genotypic resistance 58 pneumococci 58 H. pylori 58 pegylated interferon 58 S. aureus 58 chronic rhinosinusitis 58 RSV infection 58 CIMZIA ™ 58 docetaxel chemotherapy 58 tipifarnib 58 ara C 58 malignant lymphomas 58 ganetespib 58 Omacetaxine 58 visilizumab 58 adult chronic ITP 58 systemic fungal infections 58 CRBSI 58 inhibitor RG# 58 immunosuppressed patients 58 Irinotecan 58 PRT# 58 atherothrombotic disease 58 NEUGENE 58 HGS ETR1 58 mesotheliomas 58 kidney urologic 57 Helicobacter pylori infection 57 locoregional 57 type 1diabetes 57 zidovudine AZT 57 CLL SLL 57 histologies 57 gemifloxacin 57 anti angiogenic therapy 57 non metastatic osteosarcoma 57 T#I [002] 57 adenocarcinomas 57 immunopathology 57 gemcitabine Gemzar 57 IFN alpha 57 mycobacterial infections 57 lipid lowering therapies 57 complete remissions 57 Thiovir 57 mutated KRAS gene 57 chlamydial infections 57 Gleevec imatinib 57 serous ovarian cancer 57 Chronic Myelogenous Leukemia CML 57 XMRV infection 57 HER2 positive metastatic breast 57 miltefosine 57 MAGE A3 ASCI 57 CTCL 57 soft tissue sarcomas 57 APTIVUS r 57 RRMS patients 57 standard chemotherapy regimen 57 HSV2 57 ALK inhibitor 57 Malignant Melanoma 57 evaluating tivozanib 57 ceftazidime 57 atopic dermatitis 57 recurrent ovarian cancer 57 endometrial hyperplasia 57 Elacytarabine 57 Acute myeloid leukemia 57 canakinumab 57 Epratuzumab 57 Fludara 57 oral leukoplakia 57 lipid abnormalities 57 gastrointestinal stromal tumors 57 P aeruginosa 57 TKI therapy 57 PARP inhibition 57 viral kinetics 57 Waldenstrom macroglobulinemia 57 Thyroid nodules 57 HIV coinfected 57 biologic DMARD 57 EGFR TKIs 57 metastatic renal cell carcinoma 57 colorectal adenoma 57 mycophenolate mofetil 57 NXL# 57 immunomodulators 57 viremia 57 Hepatitis C Virus 57 inhalational anthrax 57 inflammatory arthritis 57 seminoma 57 nucleoside 57 amrubicin 57 Salmonella typhi 57 proteasome inhibitor 57 Chronic Lymphocytic Leukemia CLL 57 TORISEL 57 axitinib 57 null responders 57 solithromycin 57 CTAP# Capsules 57 Teriflunomide 57 juvenile idiopathic arthritis JIA 57 Neisseria gonorrhoeae 57 grade cervical dysplasia 57 B CLL 57 Talabostat 57 Respiratory Syncytial Virus RSV 57 noscapine 57 meropenem 57 refractory AML 57 etiologic agent 57 T#I mutant 57 radezolid 57 multiple myeloma 57 lupus anticoagulant 57 Glioblastoma Multiforme 57 receptor tyrosine kinase inhibitor 57 postoperative ileus 57 Seliciclib 57 micrometastases 57 PREZISTA rtv 57 cutaneous squamous cell carcinoma 57 cutaneous melanoma 57 rotaviruses 57 HAV infection 57 lomitapide 57 refractory multiple myeloma 57 gonococcal infections 57 refractory indolent non 57 intracranial hemorrhage ICH 57 NRTIs 57 hormone deprivation 57 colorectal tumors 57 hyperphosphatemia 57 cardiac toxicity 57 urethritis 57 BENLYSTA belimumab 57 preclinically 57 ABSSSI 57 Alemtuzumab 57 therapeutic regimens 57 bladder cancers 57 ALCL 57 deferiprone 57 systemically administered 57 Aplidin 57 TB bacillus 57 obatoclax 57 mapatumumab 57 arenavirus 57 chronic hepatitis cirrhosis 57 Vidaza azacitidine 57 anti angiogenic agents 57 protease inhibitor PI 57 effector function 57 B7 H3 57 cancers 57 Epidermal Growth Factor Receptor 57 MYCN amplification 57 EndoTAGTM 1 57 nasopharyngeal carcinoma 57 BARACLUDE ® 57 CCR5 receptor antagonist 57 onychomycosis 57 Chronic Myeloid Leukemia 57 WNV infections 57 S. aureus bacteria 57 decitabine 57 HuMax CD4 57 ertapenem 57 RSD# oral 57 hepatocellular carcinomas 57 ketolide antibiotic 57 malignant neoplasm 57 Anthracycline 57 herpes viruses 57 Naive Patients 57 H. influenzae 57 metastatic kidney 57 HSCT 57 dengue haemorrhagic fever DHF 57 BRCA mutations 57 Tarvacin 57 Follicular lymphoma 57 HCV protease inhibitors 57 vaccinees 57 severe neutropenia 57 gastric lymphoma 57 HBsAg 57 hepatic fibrosis 57 azacytidine 57 hypereosinophilic syndrome 57 Relapsing remitting MS 57 DMARDs 57 Dengue virus 57 busulfan 57 hemodialysis patients 57 colorectal cancer 57 physiologic mechanisms 57 HIV infected 57 alemtuzumab treated 57 transfusion transmitted 57 etiologic 57 candidiasis 57 HBV infections 57 Telintra 57 nasopharyngeal cancer 57 anti angiogenic drugs 57 investigational therapies 57 Clostridium difficile infection 57 FVIII inhibitors 57 Reverset 57 anal HPV 57 Tavocept 57 A. fumigatus 57 diabetic kidney 57 MVA BN R 57 pulmonary metastases 57 biologic therapy 57 idraparinux 57 resistant TB 57 myeloproliferative 57 interferon IFN 57 taxane chemotherapy 57 ansamycin 57 dysglycemia 57 precancerous cervical lesions 57 Cytolin ® 57 anaplastic 57 pancreatic neuroendocrine tumors 57 squamous cell carcinomas 57 Hepatitis C HCV 57 Acute Radiation Syndrome ARS 57 Onconase 57 recurrent venous thromboembolism 57 methylnaltrexone 57 C. difficile infections 57 cytoreduction 57 Lenocta 57 JAK2 inhibitor 57 chronic ITP patients 57 potent antiretroviral therapy 57 recurrent glioma 57 hepatotoxicity 57 atherothrombosis 57 Telbivudine 57 MALT lymphoma 57 ALN TTR 57 carcinoids 57 C. jejuni 57 human immunodeficiency virus 57 esophageal squamous cell carcinoma 57 targeting CD# 57 diffuse gastric 57 recombinant interferon 57 endometrial cancers 57 MyVax ® 57 TNF alpha inhibitors 57 imatinib Gleevec ® 57 KRAS mutation 57 signal transduction inhibitors 57 ALI ARDS 57 refractory NSCLC 57 Multidrug resistant 57 tumor subtypes 57 malignant ascites 57 Gastric cancer 57 huC# DM4 57 fluoroquinolone resistant 57 genital HSV 57 paroxysmal AF 57 PAOD 57 nucleoside naive 57 oral vancomycin 57 NAFLD 57 idarubicin 57 immunomodulatory 57 renal scarring 57 rhinovirus infection 57 GSK '# 57 AA Amyloidosis 57 tyrosine kinase inhibitors 57 cell lymphoma CTCL 57 palifosfamide 57 post herpetic neuralgia PHN 57 antibody MAb 57 Neulasta ® 57 lamivudine 57 antimicrobial prophylaxis 57 carcinoid cancer 57 INTELENCE 57 Intravenous CP 57 chlamydia infection 57 FOLOTYN ® 57 breast cancer subtypes 57 TB MDR TB 57 tumor recurrence 57 Febrile neutropenia 57 cytomegalovirus 57 squamous cell cancers 57 metastatic melanoma 56 abnormal Pap smears 56 IV bisphosphonates 56 relapsing remitting 56 aHUS 56 PI3K inhibitors 56 ximelagatran 56 LEUKINE 56 tumor metastases 56 causal variants 56 testicular germ cell 56 Perifosine 56 cobiprostone 56 Valortim R 56 bezafibrate 56 relapsed refractory 56 HLA B# 56 artemisinins 56 HCV polymerase inhibitor 56 log# reduction 56 pentoxifylline 56 nucleoside analogue 56 PREZISTA r 56 HbF 56 dexpramipexole 56 HspE7 56 TEAEs 56 immunocompromised patients 56 latently infected 56 M. pneumoniae 56 CANCIDAS 56 monoclonal antibody MAb 56 indinavir 56 fidaxomicin 56 telbivudine 56 Evoltra ® 56 rilonacept 56 Exelixis XL# 56 seroconversion 56 IMGN# 56 pCR 56 Myelodysplastic syndromes MDS 56 Cloretazine R 56 oesophageal adenocarcinoma 56 infections 56 neoplasia 56 enterovirus infection 56 severe hypersensitivity reactions 56 NS5b 56 cytotoxic chemotherapy 56 imatinib Gleevec 56 IFN beta 56 advanced hepatocellular carcinoma 56 Methicillin 56 Glioblastoma multiforme GBM 56 castrate resistant prostate cancer 56 anti leukemic 56 angiogenesis inhibition 56 MPS IVA 56 Tofacitinib 56 pH#N# 56 nosocomial infections 56 GBV C 56 PROSTVAC TM 56 vemurafenib 56 bacterial vaginosis BV 56 sarcomas 56 severe rotavirus gastroenteritis 56 serogroup C 56 metastatic malignant 56 personalized immunotherapy 56 mTOR inhibitors 56 GRN# 56 peginterferon alfa 2a 56 genetic variants associated 56 prostate cancer PCa 56 colorectal cancers 56 P. aeruginosa 56 shingles herpes zoster 56 clodronate 56 adenomatous polyps 56 darunavir r 56 Azilect ® 56 follicular lymphoma FL 56 haematological cancers 56 Phenoptin 56 Valcyte 56 Escherichia coli Klebsiella pneumoniae 56 renal tumors 56 oritavancin 56 relapsing multiple sclerosis 56 delafloxacin 56 humanized monoclonal antibody 56 lymphoproliferative disorders 56 virus RSV 56 diabetes mellitus DM 56 gefitinib 56 plasma kallikrein 56 cilengitide 56 tubercle bacillus 56 precursor lesions 56 hematologic toxicity 56 acne vulgaris 56 T1DM 56 immunomodulator 56 NNRTI resistant virus 56 NMIBC 56 hepatorenal syndrome 56 asymptomatic carriers 56 AML MDS 56 smoldering myeloma 56 APTIVUS 56 ZYVOX 56 Allovectin 7 ® 56 BAY #-# 56 cabazitaxel 56 ancrod 56 IGFBP 56 TroVax ® 56 refractory prostate cancer 56 SCIg 56 IRX 2 56 AZT zidovudine Retrovir 56 TNF inhibitors 56 ErbB2 positive 56 monogenic 56 Interferon alpha 56 Extensively drug 56 VTEs 56 S. aureus strains 56 MabCampath 56 paramyxoviruses 56 lymphocytosis 56 nosocomial 56 thrombotic complications 56 anthracycline containing 56 chronic viral infections 56 myelodysplastic syndrome MDS 56 oncogenic HPV types 56 macrolide antibiotics 56 teriflunomide 56 myelodysplastic syndromes MDS 56 Gleevec imatinib mesylate 56 immunotoxins 56 BCG refractory 56 Streptococcus pneumoniae 56 interstitial pneumonia 56 metastatic lesions 56 rhIGFBP 3 56 posterior uveitis 56 GW# [003] 56 curative therapy 56 alvespimycin 56 calcineurin inhibitors 56 Proxinium TM 56 invasive MRSA infections 56 BRAF mutations